Retinopathy of Prematurity (ROP)

Retinopathy of Prematurity (ROP) is the indication for 2 drugs in DrugBank. It is covered by 2 curated, structured indications.

Also known as: Retinopathy of Prematurity · ROP - Retinopathy of Prematurity · Premature Retinopathy
Classified under: Cardiovascular Diseases
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Eye Disease
Pregnancy, Puerperium, and Perinatal Conditions
Wounds and Injuries
Indicated drugs: Aflibercept
Ranibizumab

Resolves to

Vocabularies

MeSHM0018966ICD-10H35.1SNOMED CT155110004MedDRA10038933UMLSC0035344

What you can answer from here — as of October 23, 2026

2Indicated drugsWith each drug's targets and mechanism

Listed above

2Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

84Clinical trialsPhase, status and sponsor resolved per trial

1Drug reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Retinopathy of Prematurity (ROP) share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.